{Reference Type}: Journal Article
{Title}: Importance of congenital cytomegalovirus in the neonatal hearing screening program.
{Author}: Gutiérrez Posso JD;Anta Escuredo JA;Aguirre Unceta-Barrenechea A;Zabala López de Maturana JA;
{Journal}: Acta Otorrinolaringol Esp (Engl Ed)
{Volume}: 74
{Issue}: 6
{Year}: 2023 Nov-Dec 5
暂无{DOI}: 10.1016/j.otoeng.2022.12.001
{Abstract}: <B>BACKGROUND: </B>In newborns, hearing loss secondary to congenital Cytomegalovirus (CMVc) infection, despite its low prevalence, can cause a serious problem in the personal development and social integration of patients. Therefore, it is important to include the determination of CMV DNA as a neonatal screening tool.<BR><B>METHODS: </B>We have carried out a 5-year retrospective study, by describing the CMVc in the Autonomous Community of the Basque Country in newborns who did not pass the hearing screening in the early hearing loss detection program. The times of detection, confirmation (incidence) and intervention (treatment) are described.<BR><B>RESULTS: </B>Of 18,782 subjects studied, 58 (three per thousand live births) presented hearing loss. Of these, CMVc is guaranteed in four patients (one woman and three men). The mean time to hearing screening was 6.5 days (SD: ±3.69) and to detect CMV by polymerase chain reaction (PCR) in urine and saliva was 4.2 days (SD: ± 3.94). Time to confirm hearing loss by BAEP and audiological intervention 2.2 (SD: ±0.957) and 5 months (SD: ±3.741), respectively. Four hearing aid adaptations and one cochlear implant were performed.<BR><B>CONCLUSIONS: </B>Neonatal hearing screening has established itself as a good public health program. The determination of viral DNA allows an early, specific and interdisciplinary diagnosis and treatment, in which otorhinolaryngology plays a fundamental role. Our study highlights the importance of including CMV PCR as a universal screening tool.